Anti-drug antibodies in psoriasis: a critical evaluation of clinical significance and impact on treatment response

Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation

(2012) Pauline A van Schouwenburg et al.   ANNALS OF THE RHEUMATIC DISEASES

Plasma trough levels of adalimumab and infliximab in terms of clinical efficacy during the treatment of psoriasis

(2012) Hidetoshi Takahashi et al.   JOURNAL OF DERMATOLOGY

Autoantibodies in psoriasis as predictors for loss of response and anti-infliximab antibody induction

(2011) J.H.O. Hoffmann et al.   BRITISH JOURNAL OF DERMATOLOGY

Development of Antidrug Antibodies Against Adalimumab and Association With Disease Activity and Treatment Failure During Long-term Follow-up

(2011) Geertje M. Bartelds   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Efficacy and safety of ustekinumab for the treatment of moderate-to-severe psoriasis: A phase III, randomized, placebo-controlled trial in Taiwanese and Korean patients (PEARL)

(2011) Tsen-Fang Tsai et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Differential effect of drug interference in immunogenicity assays

(2011) Margreet H. Hart et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Antibodies to constant domains of therapeutic monoclonal antibodies: Anti-hinge antibodies in immunogenicity testing

(2011) Theo Rispens et al.   JOURNAL OF IMMUNOLOGICAL METHODS

The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: Results of a prospective, multicenter, open-label study

(2011) Alice B. Gottlieb et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Extent and Clinical Consequences of Antibody Formation Against Adalimumab in Patients With Plaque Psoriasis

(2010) Lidian L. A. Lecluse et al.   ARCHIVES OF DERMATOLOGY

Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions

(2010) P. ETTEHADI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

Dealing with immunogenicity of biologicals: assessment and clinical relevance

(2010) Gerrit J Wolbink et al.   CURRENT OPINION IN RHEUMATOLOGY

Therapeutic Hotline: Re-induction may be useful to manage psoriasis relapse during long-term maintenance treatment with infliximab: a retrospective analysis

(2010) Gino Vena et al.   Dermatologic Therapy

Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial

(2010) Hideshi Torii et al.   JOURNAL OF DERMATOLOGICAL SCIENCE

Anti-infliximab antibody status and its relation to clinical response in psoriatic patients: A pilot study

(2010) Esra ADIŞEN et al.   JOURNAL OF DERMATOLOGY

Long-term study of infliximab in Japanese patients with plaque psoriasis, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma

(2010) Hideshi TORII et al.   JOURNAL OF DERMATOLOGY

Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study

(2010) Akihiko ASAHINA et al.   JOURNAL OF DERMATOLOGY

The immunogenicity of humanized and fully human antibodies

(2010) Fiona A. Harding et al.   mAbs

Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis

(2010) Christopher E.M. Griffiths et al.   NEW ENGLAND JOURNAL OF MEDICINE

The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

(2010) Charlotte Krieckaert et al.   ARTHRITIS RESEARCH & THERAPY

Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation

(2009) M K de Vries et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study

(2009) G. M. Bartelds et al.   ANNALS OF THE RHEUMATIC DISEASES

Anti-adalimumab antibodies in rheumatoid arthritis patients are associated with interleukin-10 gene polymorphisms

(2009) G. M. Bartelds et al.   ARTHRITIS AND RHEUMATISM

Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial

(2009) Alice Gottlieb et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY